Christof C Smith
Overview
Explore the profile of Christof C Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
Smith C, Chai S, Washington A, Lee S, Landoni E, Field K, et al.
Cancer Immunol Res
. 2019 Sep;
7(10):1591-1604.
PMID: 31515258
Current tumor neoantigen calling algorithms primarily rely on epitope/major histocompatibility complex (MHC) binding affinity predictions to rank and select for potential epitope targets. These algorithms do not predict for epitope...
12.
Hwang B, Zhang Y, Brozowski J, Liu Z, Burette S, Lough K, et al.
Oncogene
. 2019 Aug;
38(50):7491-7503.
PMID: 31435021
BP180, also termed collagen XVII, is a hemidesmosomal transmembrane glycoprotein expressed in basal keratinocytes, and functions as a cell-matrix adhesion molecule in the dermal-epidermal junction of the skin. Its function,...
13.
Smith C, Selitsky S, Chai S, Armistead P, Vincent B, Serody J
Nat Rev Cancer
. 2019 Jul;
19(8):465-478.
PMID: 31278396
The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has accelerated within the past decade. The most commonly studied class of TSAs are those derived from non-synonymous single-nucleotide...
14.
Selitsky S, Mose L, Smith C, Chai S, Hoadley K, Dittmer D, et al.
Genome Med
. 2019 May;
11(1):36.
PMID: 31138334
Background: Measures of the adaptive immune response have prognostic and predictive associations in melanoma and other cancer types. Specifically, intratumoral T cell density and function have considerable prognostic and predictive...
15.
Smith C, Beckermann K, Bortone D, de Cubas A, Bixby L, Lee S, et al.
J Clin Invest
. 2018 Aug;
128(11):4804-4820.
PMID: 30137025
Human endogenous retroviruses (hERVs) are remnants of exogenous retroviruses that have integrated into the genome throughout evolution. We developed a computational workflow, hervQuant, which identified more than 3,000 transcriptionally active...
16.
Panda A, de Cubas A, Stein M, Riedlinger G, Kra J, Mayer T, et al.
JCI Insight
. 2018 Aug;
3(16).
PMID: 30135306
Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain. We investigated whether abnormal expression of endogenous retroviruses...
17.
Hong L, Chen Y, Smith C, Montgomery S, Vincent B, Dotti G, et al.
Cancer Immunol Res
. 2018 Aug;
6(10):1274-1287.
PMID: 30087115
Tumor antigen heterogeneity limits success of chimeric antigen receptor (CAR) T-cell therapies. Embryonal carcinomas (EC) and mixed testicular germ cell tumors (TGCT) containing EC, which are the most aggressive TGCT...
18.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2018 Jun;
23(12):3698.
PMID: 29925010
No abstract available.
19.
Saito R, Smith C, Utsumi T, Bixby L, Kardos J, Wobker S, et al.
Cancer Res
. 2018 May;
78(14):3954-3968.
PMID: 29784854
High-grade urothelial cancer contains intrinsic molecular subtypes that exhibit differences in underlying tumor biology and can be divided into luminal-like and basal-like subtypes. We describe here the first subtype-specific murine...
20.
Mi Y, Smith C, Yang F, Qi Y, Roche K, Serody J, et al.
Adv Mater
. 2018 Apr;
30(25):e1706098.
PMID: 29691900
Combination immunotherapy has recently emerged as a powerful cancer treatment strategy. A promising treatment approach utilizes coadministration of antagonistic antibodies to block checkpoint inhibitor receptors, such as antiprogrammed cell death-1...